Half-year report · Q2
7317.TEDINET S100UN3Q
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥8.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥617m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥619m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥619m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥796m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥953m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥437m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥796m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥437m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥11.0bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥9.9bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥9.7bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.8bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥4.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.2bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.2bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.7bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.3bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.2bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.0bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥528m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥262m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥414m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥616m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥546m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥34m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥183m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥146m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥37.49 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.03 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.67 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥37.05 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥44.43 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥20.43 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 56.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.0% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2024-04-01 → 2024-09-30 | ¥77m |
| Otherother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥77m |
| Otherother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥25m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥152m |
| jpcrp040300-q2r_E35560-000Medical Healthcarereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E35560-000Medical Healthcarereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E35560-000Medical Healthcarereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥924m |
| jpcrp040300-q2r_E35560-000Safetysystemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E35560-000Safetysystemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E35560-000Safetysystemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥265m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥4.9bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥4.9bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| Otherother segments | revenue | 2023-04-01 → 2023-09-30 | ¥23m |
| Otherother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥23m |
| Otherother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥9m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥147m |
| jpcrp040300-q2r_E35560-000Medical Healthcarereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E35560-000Medical Healthcarereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E35560-000Medical Healthcarereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥693m |
| jpcrp040300-q2r_E35560-000Safetysystemreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35560-000Safetysystemreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35560-000Safetysystemreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥62m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥4.2bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥4.2bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥763m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 462
| Item | Context | Value | Unit |
|---|---|---|---|
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |